

Inhibitors, Augmentive Agents in Cancer Therapy, Raven Press,
New York."

At page 28, between lines 11 and 12 please insert:

---BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the presence of diclofenac in the top skin portion after administration of the several compositions.

Figure 2 illustrates the presence of diclofenac in the bottom skin portion after administration of the several compositions.

Figure 3 illustrates the presence of diclofenac in the receptor solution after the elapse of a predetermined time.

DESCRIPTION OF EMBODIMENTS---

IN THE CLAIMS

Please delete the Claims presently pending namely, revised Claims 6 to 17 and newly added Claims 27 to 53 and substitute the enclosed Claims whose numbering starts at Claim 54 as follows:

54. A method of treating a mammal for a condition of the skin or exposed tissue selected from the group consisting of basal cell carcinoma and actinic keratosis, which method consists essentially of topically administering to the site of the condition, more than once per day over a period of days sufficient to treat the condition, a non-toxic effective dosage amount of a composition consisting essentially of

_____ (a) a non-steroidal anti-inflammatory drug (NSAID) in an amount sufficient to block prostaglandin synthesis.